Effects of progestogens on the cardiovascular system

Area of Science:

• Cardiovascular health
• Endocrinology
• Pharmacology

Background:

• Combined oral contraceptives (OCs) are widely used by women of reproductive age.
• The hormonal components of OCs, estrogen and progestogen, have been investigated for their potential cardiovascular effects.
• Understanding these effects is crucial for patient safety and informed prescribing.

Purpose of the Study:

• To investigate the role of the progestogenic component in combined oral contraceptives (OCs) regarding cardiovascular risks.
• To determine the association between OCs and arterial versus venous thromboembolic events.
• To identify contraceptive formulations that may minimize arterial disease risks.

Main Methods:

• Review of existing literature and epidemiological data on OC use and cardiovascular outcomes.
• Analysis of the specific impact of the progestogenic component on blood pressure and arterial disease.
• Comparison of risks associated with arterial versus venous thromboembolism in OC users.

Main Results:

• The progestogenic component of OCs may contribute to an elevated risk of stroke and ischemic heart disease.
• Increased blood pressure appears to be a likely mechanism mediating this arterial risk.
• The progestogenic component does not seem to influence the risk of venous thromboembolism.
• Lowering both estrogen and progestogen doses in OCs may mitigate arterial disease risks.

Conclusions:

• The progestogen in combined oral contraceptives is a potential contributor to arterial cardiovascular events.
• Minimizing progestogen and estrogen doses in OCs is recommended to reduce the risk of arterial disease.
• Further research into specific progestogen formulations and their cardiovascular impact is warranted.